Research programme: anti-cancer ligand proteins - Enchira

Drug Profile

Research programme: anti-cancer ligand proteins - Enchira

Alternative Names: ACL™ proteins; Anti-cancer ligand proteins research programme - Enchira; Receptor tyrosine kinase inhibitors research programme - Enchira

Latest Information Update: 13 Feb 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enchira Biotechnology Corporation [CEASED]
  • Class
  • Mechanism of Action Epidermal growth factor receptor antagonists; Epidermal growth factor stimulants; Insulin-like growth factor I inhibitors; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 13 Feb 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 01 Jul 2002 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top